Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
microRNA 3649 (MIR3649) is a human microRNA gene encoding a short non-coding RNA molecule that functions to regulate gene expression post-transcriptionally. Like other microRNAs, it is produced via canonical microRNA biogenesis involving cleavage by proteins such as Dicer and incorporation into the RNA-induced silencing complex (RISC), enabling it to bind and regulate target mRNAs predominantly through seed sequence complementarity[2][5][7]. While microRNAs in general play crucial roles in development, cell proliferation, apoptosis, and disease (including cancer and cardiovascular conditions), there is no evidence in current literature that MIR3649 is itself a therapeutic target, biomarker, or associated with specific diseases[1][2][3][5][7]. Its mention in databases appears to be largely categorical rather than functional. There is also no record of drug interactions or mechanisms of action directly involving MIR3649.
For microRNAs, the mechanism is binding to target mRNAs to cause mRNA degradation or translational repression. There are no drugs targeting MIR3649, so this category is not specifically applicable.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on microRNA 3649 (MIR3649).